The European Medicines Agency has begun assessing a conditional marketing authorization application (MAA) filed by Sanofi and GlaxoSmithKline plc for their COVID-19 vaccine, Vidprevtyn.
The vaccine is an adjuvanted recombinant protein-based product that includes an S-protein antigen from Sanofi and an adjuvant platform from GSK
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?